Table 3.
Treatments prescribed in management of patients with coronavirus disease 2019 (COVID-19).
| Overall (n = 222) | |
|---|---|
| Specific treatment studied for COVID-19 | 15 (7) |
| Hydroxychloroquine, n (%) | 6(40) |
| Remdesivir, n (%) | 4(27) |
| Lopinavir/ritonavir/interferon beta, n (%) | 3(20) |
| Lopinavir/ritonavir, n (%) | 2(13) |
| Corticosteroids, n (%) | 7 (3) |
| Antibiotics, n (%) | 174 (78) |
| First-line antibiotic therapy | |
| Amoxicillin, n (%) | 7 (4) |
| Amoxicillin + clavulanate, n (%) | 95 (55) |
| Third-generation cephalosporina, n (%) | 25 (14) |
| Third-generation cephalosporin + macrolideb, n (%) | 27 (16) |
| Piperacillin + tazobactam, n (%) | 9 (5) |
| Otherc, n (%) | 11 (6) |
| Second-line antibiotic therapy | |
| Amoxicillin, n (%) | 1 (3) |
| Amoxicillin + clavulanate, n (%) | 10 (29) |
| Third-generation cephalosporina, n (%) | 6 (18) |
| Third-generation cephalosporin + macrolideb, n (%) | 4 (12) |
| Piperacillin + tazobactam, n (%) | 6 (18) |
| Otherc, n (%) | 7 (21) |
a
Cefotaxime or ceftriaxone.
b
Cefotaxime associated with rovamycine.
c
Other antibiotics used: meropenem, levofloxacin, pristinamycin, linezolid, teicoplanin and metronidazole.